ArticleJournal of the Pediatric Orthopaedic Society of North America2026
Impact of Obesity on Complication Rates After Treatment of Slipped Capital Femoral Epiphysis: A Retrospective Cohort Database Study.
Article in Journal of the Pediatric Orthopaedic Society of North America, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
5 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Background: While obesity is a well-established risk factor for slipped capital femoral epiphysis (SCFE), limited data exist regarding its impact on postoperative complication rates. This study aimed to evaluate the association between obesity and complications following SCFE treatment. Methods: We queried a large national database for pediatric patients who underwent treatment for SCFE between June 2005 and June 2025. We divided this cohort into patients with obesity and patients without obesity. We matched the cohorts with a propensity scoring algorithm on a one-to-one basis, resulting in 1,175 patients in each group. We tracked outcomes including infection, pulmonary embolism (PE), chondrolysis, avascular necrosis (AVN), leg length discrepancy (LLD), and hardware complications. We used the relative risk ratio (RR) and 95% confidence intervals (CIs). Results: ≤10 (0.85%) patients developed an infection, and none developed a PE; ≤10 (0.85%) patients in each group developed chondrolysis. Thirty-eight (3.23%) patients in the obese group developed AVN after SCFE treatment, and 34 (2.89%) patients in the nonobese group developed AVN (RR = 1.12, CI: 0.71-1.76, Conclusions: Patients with obesity had increased rates of LLD and hardware complications after treatment for SCFE compared to nonobese patients. Our findings highlight the importance of ongoing follow-up and monitoring of SCFE patients to detect the development of any of these outcomes. Key Concepts: (1)Rates of infection, pulmonary embolism, and chondrolysis were low (<1%) and did not differ between obese and nonobese cohorts.(2)The rate of avascular necrosis was similar between groups.(3)In contrast, obese patients had significantly higher rates of leg length discrepancy and hardware complications. Level of Evidence: III: Retrospective cohort study.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.